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Abstract
Sarcoidosis is a multisystemic, granulomatous disease of unknown aetiology, which commonly
involves the lungs, skin and the eyes. Renal sarcoidosis is rare. Recurrent renal sarcoidosis leading
to transplant graft failure in adults has not been reported. We report a single case of steroid-resistant
sarcoid with recurrence in a renal transplant and the central nervous system that was managed with
infliximab. We describe successful resolution of granulomas in the transplant kidney and stabilization
of renal function with catastrophic central nervous system recurrence upon withdrawal of infliximab.
Case report
A 19-year-old man was diagnosed to have sarcoidosis after
presenting with lethargy, weight loss, hypercalcaemia, sple-
nomegaly and acute kidney injury (serum creatinine—400
mmol/L). He was started on prednisolone, which led to an
improvement in his renal function with his serum creati-
nine falling to 160 mmol/L. He was maintained on 5 mg of
prednisolone. He re-presented 1 year later with headache,
blurred vision and hypercalcaemia. An MRI brain showed a
9 mm lesion in the frontal lobe, which was consistent with
a granuloma. The dose of prednisolone was increased to
40 mg and azathioprine 150 mg was added. A repeat scan
showed no enhancement of the frontal lobe lesion.
In search of other organ involvement, a high resolution
CT of the lungs, lungs function tests and cardiac MRI were
done, all of which were normal. His renal function continued
to deteriorate and a repeat renal biopsy showed a globally
scarred kidney. He progressed to end-stage renal failure and
was started on haemodialysis at the age of 21 years.
He received a heart-beating deceased donor kidney the
same year and was given standard immunosuppression
with cyclosporin, mycophenolate mofetil (MMF) and predni-
solone with no induction. He had stable graft function (se-
rum creatinine ~100 mmol/L) for 4 months when his serum
creatinine climbed to 160 mmol/L. A transplant renal biopsy
showed recurrence of sarcoidosis in his transplant kidney
(Figure 1). The transplant biopsy was negative for C4d stain-
ing and no donor-specific antigens were detected in the
patient’s serum. There was no evidence of infectious causes
of granulomatous disease. He was pulsed with methylpred-
nisolone (500 mg) and the subsequent dose of prednisolone
was increased to 20 mg. The serum creatinine fell to 139
mmol/L. Due to lack of further improvement in renal func-
tion, a biopsy was repeated 2 months later (Figure 2).
At this juncture, this 21-year-old man was on high-dose
steroids and had ongoing active granulomatous tubulo-
interstitial nephritis (TIN) potentially rendering him un-
transplantable in the future. He was becoming increasingly
Cushingoid with rising blood glucose levels.
We treated this patient with infliximab 5 mg/kg at 0, 2
and 6 weeks as induction and 8 weekly maintenance in-
fusions. His cyclosporine was withdrawn with MMF and
prednisolone (25 mg) ongoing. At Month 4 re-assessment,
his prednisolone was at 15 mg with serum creatinine,
110 mmol/L. He had had four infliximab infusions completed
without any adverse events. A repeat renal biopsy was per-
formed (Figure 3). This showed marked reduction in the
granulomatous TIN.
Infliximab was withdrawn after 10 infusions. His renal
function was stable with a serum creatinine of 110 mmol/L.
He re-presented after a few months with spastic parapare-
sis. An MRI brain and spinal cord showed multiple inflam-
matory lesions. His transplant function remained stable at
this point. He was diagnosed with aggressive neurosarcoid.
He was treated with pulsed steroids and infliximab was
recommenced. He is currently on 8 weekly infusions of in-
fliximab. His renal function continues to remain stable. He
remains wheelchair bound from his paraparesis.
Discussion
Renal involvement in sarcoidosis is rare. Its recurrence
after transplantation usually follows a mild clinical course
and is responsive to increased immunosuppression. It has
been reported recently that it is safe to perform renal
transplantation in sarcoidosis with close clinical and his-
tological monitoring [1]. Graft loss from sarcoidosis has not
been reported in adults. There has been one case report of
the use of infliximab in a paediatric renal transplant recip-
ient with steroid resistant sarcoidosis [2].
There is good evidence on the pathologic role of TNF-a
in sarcoidosis. The granulomas consist of a core of mac-
rophages, epithelioid cells and multinucleated giant cells
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surrounded by monocytes, lypmphocytes, fibroblasts and
mast cells. TNF-a has a role to play in monocyte recruitment
and cytokine-mediated T-lymphocyte activation and prolif-
eration. It also promotes macrophage aggregation via up-
regulation of Intercellular Adhesion Molecule-1 (ICAM-1).
Infliximab is a chimaeric monoclonal antibody, which
binds free TNF-a and sometimes cell surface TNF-a. Menon
et al. [3] have reported the use of infliximab in interferon-
a-associated renal sarcoid in a single case report. There
has been one randomized controlled trial comparing pla-
cebo and infliximab in pulmonary sarcoid (Baughman et al.
[4]). They randomized 138 patients with chronic pulmonary
sarcoid to receive placebo or infliximab at 3 or 5 mg/kg body
weight. In the infliximab groups, there was combined
increase of 2.5% in FVC compared to no change in the
placebo group (P ¼ 0.038) at 24 weeks. There was no
difference in the secondary end points for any of the other
criteria. The data to support the use of infliximab in renal
sarcoid is very poor and is limited to very few anecdotal
case reports.
The long-term safety of biological agents has been
studied in the patients undergoing treatment for autoim-
mune diseases like rheumatoid arthritis. In an overview
assessing the safety of biological agents, Khraishi et al.
[5] reported a significantly increased risk of reactivation
of TB (54/100 000 treated) and opportunistic infections like
aspergillosis, listeria, pneumocystis and herpes immedi-
ately after starting therapy [6]. There is increased risk of
malignancy with immunosuppression as has been seen in
renal transplantation [7].
In an overview of the US National Databank for Rheumatic
Diseases, Wolfe et al. [8] have reported an increased risk of
melanoma, odds ratio [OR 2.6 (95% confidence interval (CI)
1.0–6.7) P ¼ 0.056] and non-melanotic skin cancer OR [1.7
(95% CI 1.3–2.2) P < 0.001] with the use of infliximab. There
was no increased risk of any other malignancies.
In summary, we report successful resolution of sarcoid
granulomas in a renal transplant with infliximab. With-
drawal of infliximab led to a catastrophic relapse in the
brain and the spinal cord. There have been no adverse
events related to the infusion or therapy. This case is en-
couraging as infliximab led to a resolution of renal sarcoid
granulomas and stabilization of graft function.
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caseating granuloma. No evidence of rejection.
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